Conjugate including a severable linker
JP2026514774A5Pending Publication Date: 2026-07-01ASTRAZENECA AB
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- ASTRAZENECA AB
- Filing Date
- 2024-04-09
- Publication Date
- 2026-07-01
AI Technical Summary
Technical Problem
There is a need for antibody drug conjugates (ADCs) with β-glucuronidase-cleavable linkers that can selectively deliver drugs to biological targets while maintaining desirable physicochemical properties such as solubility and lipophilicity, particularly for the treatment of diseases like cancer.
Method used
Conjugates containing linkers of specific formulas (I), (IC), (IM), or (IT) with defined structures and connections, which allow for enzymatic cleavage and improved stability, solubility, and reduced toxicity, suitable for cancer treatment.
Benefits of technology
The conjugates exhibit enhanced efficacy and favorable properties, including higher stability, solubility, and reduced toxicity, making them particularly suitable for cancer therapy.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000000_0001_ABST 
Figure 00000000_0000_ABST
Abstract
This specification relates to conjugates containing a linker of formula (IA) and pharmaceutically acceptable salts thereof. This specification also relates to the use of conjugates for the treatment of diseases such as cancer and intermediates useful for the synthesis of conjugates. [Formula 1] JPEG2026514774000204.jpg30128
Need to check novelty before this filing date? Find Prior Art